We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+36.02%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$969M
AUM Growth
+$247M
Cap. Flow
+$29.4M
Cap. Flow %
3.03%
Top 10 Hldgs %
77.9%
Holding
37
New
5
Increased
8
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
+$15.2M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$14.9M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$10.7M
4
XLRN
Acceleron Pharma
XLRN
+$10.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$10.3M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$22.9M
2
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$17M
3
NTRA icon
Natera
NTRA
+$9.45M
4
AGRX
Agile Therapeutics
AGRX
+$6.49M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$4.56M

Sector Composition

Rank Sector Weight
1 Healthcare 96.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.12B
$230M 23.74%
7,088,651
– –
ACHN
2
DELISTED
Achillion Pharmaceuticals
ACHN
$97.5M 10.05%
12,033,220
– –
ASND icon
3
Ascendis Pharma A/S
ASND
$16.5B
$74M 7.63%
3,681,491
+268,634
+8% +$4.43M
AVXS
4
DELISTED
AveXis, Inc. Common Stock
AVXS
$71.4M 7.36%
1,732,274
+392,892
+29% +$14.9M
SIOX
5
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$70M 7.22%
625,000
– –
NKTR icon
6
Nektar Therapeutics
NKTR
$2.39B
$63M 6.49%
244,277
+29,287
+14% +$7.54M
ARDX icon
7
Ardelyx
ARDX
$1.24B
$42.3M 4.36%
3,266,045
+953,802
+41% +$9.99M
ACRS icon
8
Aclaris Therapeutics
ACRS
$715M
$39.6M 4.09%
1,547,152
-1,080,567
-41% -$22.9M
TGTX icon
9
TG Therapeutics
TGTX
$8.19B
$35.8M 3.7%
4,631,114
+99,400
+2% +$639K
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
$31.5M 3.24%
2,656,166
+204,929
+8% +$1.89M
NGNE icon
11
Neurogene
NGNE
$672M
$29.3M 3.02%
109,599
+25,000
+30% +$5.04M
AIMT
12
DELISTED
Aimmune Therapeutics
AIMT
$19.4M 2%
1,292,940
– –
FOMX
13
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$16.9M 1.74%
+1,820,138
New +$15.2M
PTGX icon
14
Protagonist Therapeutics
PTGX
$8.55B
$15.9M 1.64%
+754,411
New +$10.3M
TARA icon
15
Protara Therapeutics
TARA
$214M
$15.2M 1.57%
40,673
– –
DRNA
16
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$14.3M 1.47%
2,428,571
– –
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$2.42B
$13.2M 1.36%
2,989,795
– –
SBBP
18
DELISTED
Strongbridge Biopharma plc.
SBBP
$13.1M 1.35%
2,501,667
-173,671
-6% -$783K
BOLD
19
DELISTED
Audentes Therapeutics, Inc
BOLD
$12.6M 1.3%
+707,426
New +$10.7M
DMTX
20
DELISTED
Dimension Therapeutics, Inc
DMTX
$12.4M 1.28%
1,548,033
– –
XLRN
21
DELISTED
Acceleron Pharma
XLRN
$11.5M 1.19%
+318,565
New +$10.6M
ARWR icon
22
Arrowhead Research
ARWR
$12.1B
$11.2M 1.16%
+1,525,424
New +$9.89M
TENX icon
23
Tenax Therapeutics
TENX
$393M
$5.53M 0.57%
75
– –
ONC
24
BeOne Medicines Ltd
ONC
$33.9B
$5.24M 0.54%
170,000
– –
ARCT icon
25
Arcturus Therapeutics
ARCT
$165M
$5.05M 0.52%
292,108
-141,165
-33% -$4.56M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, RA Capital Management held 37 positions worth $969M, up 34% from $722M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

RA Capital Management deployed $29.4M of net new capital in Q3 2016, opening 5 new positions and adding to 8 existing holdings. Its largest new stake was Foamix Pharmaceuticals Ltd. Ordinary Shares: 1,820,138 shares worth $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $22.9M trimmed.

  • RA Capital Management's largest Q3 2016 buy was Foamix Pharmaceuticals Ltd. Ordinary Shares: 1,820,138 shares worth $16.9M.
  • RA Capital Management added most to AveXis, Inc. Common Stock in Q3 2016, an estimated $14.9M increase.
  • RA Capital Management's biggest Q3 2016 reduction was Aclaris Therapeutics, cutting an estimated $22.9M.
  • RA Capital Management fully exited VITAE PHARMACEUTICALS INC COMMON STOCK in Q3 2016, selling an estimated $17M.
  • RA Capital Management's ten largest holdings make up 78% of its $969M portfolio in Q3 2016.
  • RA Capital Management opened 5 new positions and closed 7 in Q3 2016.
  • RA Capital Management's portfolio value rose 34% quarter-over-quarter to $969M.

Based on RA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.